Top

Published in:

01-02-2020 | Breast Cancer | Epidemiology

25-Hydroxyvitamin D at time of breast cancer diagnosis and breast cancer survival

Authors: Charlotte Kanstrup, Dorthe Teilum, Lars Rejnmark, Janne Villemoes Bigaard, Pia Eiken, Niels Kroman, Anne Tjønneland, Mathias Kvist Mejdahl

Published in: Breast Cancer Research and Treatment | Issue 3/2020

Abstract

Purpose

Previous studies have shown that low levels of 25-hydroxyvitamin D (25(OH)D) are associated with a poorer breast cancer survival. The relationship between vitamin D status and breast cancer outcomes is however still debated. The aim of the present study was to investigate the association between 25(OH)D blood levels measured at time of diagnosis and event-free survival (EFS) and overall survival (OS) in a large cohort of patients with early-stage primary invasive breast cancer.

Methods

From April 2008 to April 2013, 25(OH)D status was measured at time of diagnosis in all women operated for early stage primary invasive breast cancer at Rigshospitalet, Copenhagen, Denmark. Associations between 25(OH)D and EFS and OS were investigated using a Cox Proportional hazards model, adjusting for age, disease characteristics, time period, and BMI. Differences in survival were evaluated by hazard ratios (HR).

Results

In the present study, 2510 women with primary invasive breast cancer were included. Women with the lowest 25(OH)D levels (≤ 52 nmol/L) had an inferior EFS with a HR of 1.63 (95% CI 1.21–2.19) compared to women in the third quartile (76–99 nmol/L). Women with the highest 25(OH)D levels (≥ 99 nmol/L) also had an inferior EFS with a HR of 1.37 (95% CI 1.02–1.83). Plotting 25(OH)D status against EFS, the association was inversely J-shaped. For OS, a similar association with 25(OH)D status was observed.

Conclusion

We confirmed previous findings suggesting that a low 25(OH)D status is associated with an inferior breast cancer survival, but unlike previous findings, we found an indication of poorer breast cancer survival also among women with high 25(OH)D levels.

Available only for authorised users

Holick MF (2007) Vitamin D deficiency. N Engl J Med 357(3):266–281CrossRef

Feldman D et al (2014) The role of vitamin D in reducing cancer risk and progression. Nat Rev Cancer 14(5):342–357CrossRef

Bikle DD (2014) Vitamin D metabolism, mechanism of action, and clinical applications. Chem Biol 21(3):319–329CrossRef

Kim Y, Je Y (2014) Vitamin D intake, blood 25(OH)D levels, and breast cancer risk or mortality: a meta-analysis. Br J Cancer 110(11):2772–2784CrossRef

Yao S et al (2017) Association of serum level of vitamin d at diagnosis with breast cancer survival: a case-cohort analysis in the pathways study. JAMA Oncol 3(3):351–357CrossRef

Hatse S et al (2012) Vitamin D status at breast cancer diagnosis: correlation with tumor characteristics, disease outcome, and genetic determinants of vitamin D insufficiency. Carcinogenesis 33(7):1319–1326CrossRef

Vrieling A et al (2014) Circulating 25-hydroxyvitamin D and postmenopausal breast cancer survival: influence of tumor characteristics and lifestyle factors? Int J Cancer 134(12):2972–2983CrossRef

Goodwin PJ et al (2009) Prognostic effects of 25-hydroxyvitamin D levels in early breast cancer. J Clin Oncol 27(23):3757–3763CrossRef

Tretli S et al (2012) Serum levels of 25-hydroxyvitamin D and survival in Norwegian patients with cancer of breast, colon, lung, and lymphoma: a population-based study. Cancer Causes Control 23(2):363–370CrossRef

10.

Jacobs ET et al (2016) Vitamin D and colorectal, breast, and prostate cancers: a review of the epidemiological evidence. J Cancer 7(3):232–240CrossRef

11.

Villasenor A et al (2013) Associations of serum 25-hydroxyvitamin D with overall and breast cancer-specific mortality in a multiethnic cohort of breast cancer survivors. Cancer Causes Control 24(4):759–767CrossRef

12.

Blichert-Toft M, Christiansen P, Mouridsen HT (2008) Danish Breast Cancer Cooperative Group–DBCG: history, organization, and status of scientific achievements at 30-year anniversary. Acta Oncol 47(4):497–505CrossRef

13.

Christiansen P et al (2016) Danish Breast Cancer Cooperative Group. Clin Epidemiol 8:445–449CrossRef

14.

Ejlertsen B et al (2018) Forty years of landmark trials undertaken by the Danish Breast Cancer Cooperative Group (DBCG) nationwide or in international collaboration. Acta Oncol 57(1):3–12CrossRef

15.

Elston CW, Ellis IO (2002) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. C. W. Elston & I. O. Ellis. Histopathology, 1991; 19; 403–410. Histopathology 41(3a):151–152 (discussion 152–153) CrossRef

16.

Maunsell Z, Wright DJ, Rainbow SJ (2005) Routine isotope-dilution liquid chromatography-tandem mass spectrometry assay for simultaneous measurement of the 25-hydroxy metabolites of vitamins D2 and D3. Clin Chem 51(9):1683–1690CrossRef

17.

Hojskov CS, Heickendorff L, Moller HJ (2010) High-throughput liquid-liquid extraction and LCMSMS assay for determination of circulating 25(OH) vitamin D3 and D2 in the routine clinical laboratory. Clin Chim Acta 411(1–2):114–116CrossRef

18.

Rejnmark L et al (2011) Determinants of plasma PTH and their implication for defining a reference interval. Clin Endocrinol (Oxf) 74(1):37–43CrossRef

19.

Phinney KW (2008) Development of a standard reference material for vitamin D in serum. Am J Clin Nutr 88(2):511S–512SCrossRef

20.

Carter GD et al (2004) Measurement of Vitamin D metabolites: an international perspective on methodology and clinical interpretation. J Steroid Biochem Mol Biol 89–90(1–5):467–471CrossRef

21.

Gail MH et al (2016) Calibration and seasonal adjustment for matched case-control studies of vitamin D and cancer. Stat Med 35(13):2133–2148CrossRef

22.

Harrell FE, Lee KL (1986) Verifying assumptions of the Cox proportional hazards model. In: Proceedings of the eleventh annual SAS Users group international conference, Cary, NC, pp 823–828

23.

Piura E et al (2009) Serum 1-OH vitamin D (D) and prognosis of postmenopausal breast cancer (BC) patients: NCIC-CTG MA14 trial. J Clin Oncol 27(15S):534–534

24.

Keum N, Giovannucci E (2014) Vitamin D supplements and cancer incidence and mortality: a meta-analysis. Br J Cancer 111(5):976–980CrossRef

25.

Manson JE et al (2019) Vitamin D supplements and prevention of cancer and cardiovascular disease. N Engl J Med 380(1):33–44CrossRef

26.

Durup D et al (2012) A reverse J-shaped association of all-cause mortality with serum 25-hydroxyvitamin D in general practice: the CopD study. J Clin Endocrinol Metab 97(8):2644–2652CrossRef

27.

Zittermann A et al (2012) Vitamin D deficiency and mortality risk in the general population: a meta-analysis of prospective cohort studies. Am J Clin Nutr 95(1):91–100CrossRef

28.

Sempos CT et al (2013) Is there a reverse J-shaped association between 25-hydroxyvitamin D and all-cause mortality? Results from the U.S. nationally representative NHANES. J Clin Endocrinol Metab 98(7):3001–3009CrossRef

29.

Melamed ML et al (2008) 25-Hydroxyvitamin D levels and the risk of mortality in the general population. Arch Intern Med 168(15):1629–1637CrossRef

30.

Durup D et al (2015) A reverse J-shaped association between serum 25-hydroxyvitamin D and cardiovascular disease mortality: the CopD study. J Clin Endocrinol Metab 100(6):2339–2346CrossRef

31.

Robsahm TE, Schwartz GG, Tretli S (2013) The inverse relationship between 25-hydroxyvitamin D and cancer survival: discussion of causation. Cancers (Basel) 5(4):1439–1455CrossRef

32.

Hu K et al (2018) Circulating vitamin D and overall survival in breast cancer patients: a dose-response meta-analysis of cohort studies. Integr Cancer Ther 17(2):217–225CrossRef

33.

Cao Y et al (2018) Vitamin D aggravates breast cancer by inducing immunosuppression in the tumor bearing mouse. Immunotherapy 10(7):555–566CrossRef

34.

Hofmann JN et al (2010) long-term variation in serum 25-hydroxyvitamin D concentration among participants in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiol Biomarkers Prev 19(4):927–931CrossRef

Title: 25-Hydroxyvitamin D at time of breast cancer diagnosis and breast cancer survival
Authors: Charlotte Kanstrup
Dorthe Teilum
Lars Rejnmark
Janne Villemoes Bigaard
Pia Eiken
Niels Kroman
Anne Tjønneland
Mathias Kvist Mejdahl
Publication date: 01-02-2020
Publisher: Springer US
Keywords: Breast Cancer
Breast Cancer
Published in: Breast Cancer Research and Treatment / Issue 3/2020
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-019-05486-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2020

Histone deacetylase (HDAC) inhibitors and doxorubicin combinations target both breast cancer stem cells and non-stem breast cancer cells simultaneously

Breast density measured volumetrically in a clinical environment: cross-sectional study with photon counting technology

The prognostic value of NRF2 in breast cancer patients: a systematic review with meta-analysis

The orphan nuclear receptor estrogen-related receptor beta (ERRβ) in triple-negative breast cancer

The influence on quality of life of intermittent scheduling in first- and second-line chemotherapy of patients with HER2-negative advanced breast cancer

Adjuvant addition of capecitabine to early-stage triple-negative breast cancer patients receiving standard chemotherapy: a meta-analysis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer